Slide 1: Q1 2026 Conference Call Note
Q1 2026 Conference Call Note Wacker Chemie AG Dr. Christian Hartel (CEO), Dr. Tobias Ohler (CFO) April 29th, 2026
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on man
Slide 3: WACKER Q1 2026 Highlights
WACKER Q1 2026 Highlights Overview Financials Operations Sustainability Sales lower yoy primarily due to negative FX PACE cost program underway, savings Enabling Sustainable effects, EBITDA markedly higher on cost clearly support Q1/26 performance. measures and pull-forward effects > €300m in saving
Slide 4: FY 2026 Outlook Updated
FY 2026 Outlook Updated EBITDA Range Unchanged, Sales Revised Upwards FY 2026 Group Outlook 2026 • Sales: High-single digit percentage higher year over year (previous guidance: low single-digit percentage higher) Outlook • Price increases announced late March in Silicones and Polymers to address ris
Slide 5: Q1 2026 EBITDA At €173m, Supported by PACE And Pull-Forwards
Q1 2026 EBITDA At €173m, Supported by PACE And Pull-Forwards Profit & loss Q1 2026 Q1 2025 Q1 comments Sales 1,406 1,478 • Sales -5% yoy FX -4%, Price -1%, Volume/Mix 0% Gross profit 220 192 • EBITDA +45% yoy Gross profit % 15.6% 13.0% • Performance supported by PACE cost program and pull-forward ef
Slide 6: Financials with €1.44bn in Liquidity and €3.82bn in Equity
Financials with €1.44bn in Liquidity and €3.82bn in Equity Balance sheet Assets Balance sheet per 03/31/26 Liabilities €8.4bn €8.5bn €8.4bn €8.5bn Cash & securities: • High level of liquidity at €1.44bn 52% 51% 45% 45% Accounts receivables: • + €112m higher YTD due to seasonality in Chems 12% 11% Fi
Slide 7: Silicones: EBITDA Benefited From PACE Cost Program
Silicones: EBITDA Benefited From PACE Cost Program Quarterly figures Q1 Comments Sales (€m) -5% • Sales supported by seasonal recovery and stronger 745 713 708 standards volumes 673 602 • EBITDA benefited yoy from PACE cost program • Order intake improved on pull-forward effects Q1 2025 Q2 2025 Q3 2
Slide 8: Polymers: Cost Savings Supported EBITDA
Polymers: Cost Savings Supported EBITDA Quarterly figures Sales (€m) Q1 Comments -8% • Sales yoy held back by adverse FX effects, softer prices 360 363 344 and overall lower volumes 312 333 • EBITDA yoy benefited from PACE cost program and lower raw materials Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Slide 9: Biosolutions: Cost Performance And Project Timing Support Q1/26
Biosolutions: Cost Performance And Project Timing Support Q1/26 Quarterly figures Sales (€m) Q1 Comments +9% • Sales supported by increased project business and 93 100 benefitted from both delayed Q4/25 completions and 91 87 89 projects pulled forward from Q2/26 • EBITDA driven by higher sales and c
Slide 10: Polysilicon: Strong Semi Demand, Uncertainty in Solar Continues
Polysilicon: Strong Semi Demand, Uncertainty in Solar Continues Quarterly figures Sales (€m) Q1 Comments -8% • Strong semi demand, volumes sold significantly higher yoy 245 218 197 222 226 • Low solar demand, ASP lower yoy • EBITDA at prior-year level with better mix and good cost performance offset
Slide 11: Net Debt At €964m
Net Debt At €964m Year-to-date development of net debt 77 -886 0 -109 -29 -18 -964 Net financial debt Cash flow from Cash flow from Dividend paid, Lease liabilities Fx, others Net financial debt 31. Dec. 2025 operating activities investing before WACKER 31. Mar. 2026 securities Wacker Chemie AG, Q1
Slide 12: Q&A
Q&A
Slide 13: Guidance FY 2026 Updated
Appendix Guidance FY 2026 Updated In €m FY 2025 Outlook 2026 Sales 5,485 High single-digit percentage higher yoy1 EBITDA 427 In the range from €550 to 700m EBITDA margin (%) 7.8 Low double-digit percentage figure Included in EBITDA / EBIT: -103 0 restructuring expenses Net cash flow -4 Positive, sig
Slide 14: Q1 Results
Appendix Q1 Results Year-over-year performance In €m Q1 2026 Q1 2025 % Sales 1,406 1,478 -5% EBITDA reported 173 119 45% EBITDA-margin 12.3% 8.1% - EBIT 52 -7.4 - EBIT-margin 3.7% -0.5% - Net income for the period 15 -3.4 - EPS 0.21 -0.16 - CapEx 61 93 -35% Net cash flow -32 -165 -81% Net financial
Slide 15: Segment Performance
Appendix Segment Performance Q1 results for the group and by segment In €m Q1 2026 Q1 2025 Sales EBITDA % Sales EBITDA % Chemicals 1,041 166 16.0 1,105 141 12.7 SILICONES 708 117 16.5 745 103 13.9 POLYMERS 333 50 14.9 360 37 10.4 BIOSOLUTIONS 100 13 13.5 91 5 5.8 POLYSILICON 226 23 10.0 245 24 9.9 O
Slide 16: WACKER: Issuer, Contact and Additional Information
WACKER: Issuer, Contact and Additional Information Investor relations contacts Financial Calendar May 6, 2026 AGM Joerg Hoffmann, CFA July 30, 2026 Q2 2026 Results Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com Oct. 29, 2026 Q3 2026 Results Scott McCollister Tel. +49 89 6279 1560 | scott.mccollis